Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ConocoPhillips stock logo
COP
ConocoPhillips
$134.23
0.0%		$120.15
$85.57
▼
$137.42
$161.26B0.136.57 million shs5.40 million shs
MorphoSys AG stock logo
MOR
MorphoSys
$18.96
$18.96
$4.18
▼
$19.50
$2.86B1.21.02 million shsN/A
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ConocoPhillips stock logo
COP
ConocoPhillips
0.00%+2.89%+14.26%+12.85%+44.38%
MorphoSys AG stock logo
MOR
MorphoSys
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ConocoPhillips stock logo
COP
ConocoPhillips
$134.23
0.0%		$120.15
$85.57
▼
$137.42
$161.26B0.136.57 million shs5.40 million shs
MorphoSys AG stock logo
MOR
MorphoSys
$18.96
$18.96
$4.18
▼
$19.50
$2.86B1.21.02 million shsN/A
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ConocoPhillips stock logo
COP
ConocoPhillips
0.00%+2.89%+14.26%+12.85%+44.38%
MorphoSys AG stock logo
MOR
MorphoSys
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ConocoPhillips stock logo
COP
ConocoPhillips
2.63
Moderate Buy$140.294.52% Upside
MorphoSys AG stock logo
MOR
MorphoSys
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest COP, AFX, MOR, and DRW3 Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/24/2026
ConocoPhillips stock logo
COP
ConocoPhillips
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingUnderperform$168.00
8/19/2026
ConocoPhillips stock logo
COP
ConocoPhillips
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$147.00 ➝ $151.00
8/19/2026
ConocoPhillips stock logo
COP
ConocoPhillips
Argus logo
Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$136.00 ➝ $153.00
8/17/2026
ConocoPhillips stock logo
COP
ConocoPhillips
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$155.00 ➝ $150.00
8/12/2026
ConocoPhillips stock logo
COP
ConocoPhillips
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$143.00 ➝ $153.00
8/11/2026
ConocoPhillips stock logo
COP
ConocoPhillips
Susquehanna logo
Susquehanna
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetPositive$155.00 ➝ $161.00
8/10/2026
ConocoPhillips stock logo
COP
ConocoPhillips
Freedom Capital logo
Freedom Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
8/10/2026
ConocoPhillips stock logo
COP
ConocoPhillips
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetHold$115.00 ➝ $130.00
8/7/2026
ConocoPhillips stock logo
COP
ConocoPhillips
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$147.00
8/7/2026
ConocoPhillips stock logo
COP
ConocoPhillips
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$183.00 ➝ $189.00
(Data available from 9/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ConocoPhillips stock logo
COP
ConocoPhillips
$61.55B2.62$15.87 per share8.46$52.19 per share2.57
MorphoSys AG stock logo
MOR
MorphoSys
$238.28M11.99N/AN/A$0.35 per share54.17
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ConocoPhillips stock logo
COP
ConocoPhillips
$7.99B$7.5617.7614.311.4114.22%14.72%7.77%11/5/2026 (Estimated)
MorphoSys AG stock logo
MOR
MorphoSys
-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/A

Latest COP, AFX, MOR, and DRW3 Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
ConocoPhillips stock logo
COP
ConocoPhillips
$2.90$3.24+$0.34$3.23$18.79 billion$19.52 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ConocoPhillips stock logo
COP
ConocoPhillips
$3.362.50%+13.48%44.44%N/A
MorphoSys AG stock logo
MOR
MorphoSys
N/AN/AN/AN/AN/A

Latest COP, AFX, MOR, and DRW3 Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/6/2026
ConocoPhillips stock logo
COP
ConocoPhillips
quarterly$0.842.63%8/17/20268/17/20269/1/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ConocoPhillips stock logo
COP
ConocoPhillips
0.35
1.54
1.39
MorphoSys AG stock logo
MOR
MorphoSys
4.98
1.38
1.38

Institutional Ownership

CompanyInstitutional Ownership
ConocoPhillips stock logo
COP
ConocoPhillips
82.36%
MorphoSys AG stock logo
MOR
MorphoSys
18.38%

Insider Ownership

CompanyInsider Ownership
ConocoPhillips stock logo
COP
ConocoPhillips
0.09%
MorphoSys AG stock logo
MOR
MorphoSys
0.05%
CompanyEmployeesShares OutstandingFree FloatOptionable
ConocoPhillips stock logo
COP
ConocoPhillips
9,9001.20 billion1.20 billionOptionable
MorphoSys AG stock logo
MOR
MorphoSys
730150.62 million150.55 millionNot Optionable

Recent News About These Companies

Morphosys AG : MOR
May 31, 2026  |  247wallst.comhttps://247wallst.com/companies/mor/
Patent case unblocks antibody businesses
May 25, 2026  |  nature.comN
Novartis Drug Ianalumab Succeeds in Second Indication
December 11, 2025  |  thesiliconreview.comT
Novartis notches another win for drug acquired in MorphoSys deal
December 9, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/novartis-notches-another-win-drug-120400048.html
Novartis drug reduces Sjögren's activity, patient burden in late-stage trials despite notable placebo effect
October 29, 2025  |  fiercebiotech.comF
Novartis' Avidity Deal: Growth Accretive, Multiple Gated By Execution
October 27, 2025  |  seekingalpha.comhttps://seekingalpha.com/article/4833719-novartis-avidity-deal-growth-accretive-multiple-gated-by-execution
Myelofibrosis Market Overview: Epidemiology, Therapies, and Key Players include AbbVie, Morphosys, Geron, Bristol Myers Squibb, Kartos Therapeutics, Karyopharm Therapeutics, NS ...
October 7, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/GetNews/35260290/myelofibrosis-market-overview-epidemiology-therapies-and-key-players-include-abbvie-morphosys-geron-bristol-myers-squibb-kartos-therapeutics-karyopharm-therapeutics-ns-pharma-galecto-biotech/
MorphoSys takeover delivers phase 3 win for Novartis
August 11, 2025  |  pharmaphorum.comP
Novartis drug acquired in Morphosys deal succeeds against tough-to-treat autoimmune disease
August 11, 2025  |  biopharmadive.comB
Maxion Therapeutics Appoints Dr. Stefan Härtle as Chief Development Officer
June 17, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/maxion-therapeutics-appoints-dr-stefan-120000645.html
Essential Thrombocythemia Market Set for Significant Growth Across 7MM | DelveInsight
March 21, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/GetNews/31518365/essential-thrombocythemia-market-set-for-significant-growth-across-7mm-delveinsight/
Royalty Pharma targets $3B share buyback and projects 4-9% growth in 2025 portfolio receipts
February 12, 2025  |  seekingalpha.comhttps://seekingalpha.com/news/4406332-royalty-pharma-targets-3b-share-buyback-and-projects-4minus-9-percent-growth-in-2025
VIDEO: Triplet therapy improved PFS in relapsed, refractory follicular lymphoma
January 15, 2025  |  healio.comH
Novartis closing Morphosys facilities, laying off 330 workers
January 8, 2025  |  bioworld.comB
Swiss pharma giant Novartis to close biotech firm Morphosys
December 20, 2024  |  swissinfo.chS
Novartis to shut MorphSys sites amid pelabresib delay
December 20, 2024  |  thepharmaletter.comT
Novartis Cuts MorphoSys Sites in Boston, Munich, Affecting 330 Jobs
December 19, 2024  |  biospace.comB
Novartis sheds MorphoSys staff, sites after pelabresib delay
December 19, 2024  |  pharmaphorum.comP
Novartis shutters MorphoSys sites, lays off staff
December 19, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/novartis-shutters-morphosys-sites-lays-121200979.html
Some 330 jobs hit as Novartis closes Morphosys, WiWo reports
December 19, 2024  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/some-330-jobs-hit-novartis-closes-morphosys-wiwo-reports-2024-12-19/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Trading floor with digital stock displays and workstations, overlaid with the text "S&P 500".
5 Reasons the S&P 500 Could Keep Rallying Through Year-End
By Thomas Hughes | August 20, 2026
Williams Sonoma circular logo sign on a wall surrounded by kitchenware, bowls, a pepper mill, and cutting board.
Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
By Thomas Hughes | August 26, 2026
Illustration of a glass globe surrounded by gold coin stacks, symbolizing global financial markets and investment.
This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
By Jessica Mitacek | August 17, 2026
Conceptual illustration of a stock price chart rising sharply in green before turning red at the peak, set against storm clouds.
3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
By Dan Schmidt | August 22, 2026
Microsoft logo in faceted glass sphere in data center.
Microsoft's Sell-Off May Be a Gift, Not a Warning
By Chris Markoch | August 21, 2026
ConocoPhillips stock logo

ConocoPhillips NYSE:COP

$134.23 -0.03 (-0.02%)
As of 09/4/2026 03:58 PM Eastern

ConocoPhillips explores for, produces, transports, and markets crude oil, bitumen, natural gas, liquefied natural gas (LNG), and natural gas liquids in the United States, Canada, China, Libya, Malaysia, Norway, the United Kingdom, and internationally. The company's portfolio includes unconventional plays in North America; conventional assets in North America, Europe, Asia, and Australia; global LNG developments; oil sands assets in Canada; and an inventory of global exploration prospects. ConocoPhillips was founded in 1917 and is headquartered in Houston, Texas.

MorphoSys stock logo

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)
As of 09/4/2026

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas